Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the placebo‐controlled phase III ORATORIO study (NCT01194570), we investigate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Neurol
Hlavní autoři: Wolinsky, Jerry S., Montalban, Xavier, Hauser, Stephen L., Giovannoni, Gavin, Vermersch, Patrick, Bernasconi, Corrado, Deol‐Bhullar, Gurpreet, Garren, Hideki, Chin, Peter, Belachew, Shibeshih, Kappos, Ludwig
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220799/
https://ncbi.nlm.nih.gov/pubmed/30155979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25313
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky